Lipid oxidative stress and the anti-inflammatory properties of statins and ACE inhibitors

Journal of Renal Nutrition

Volumn 15, Issue 1, 2005, Pages 71-76

  Cattaneo, Dario ^a   Remuzzi, Giuseppe ^a,b  

^a OSPEDALI RIUNITI   (Italy)

^b MARIO NEGRI INST PHARMACOL RES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LISINOPRIL; LOSARTAN; MEVALONIC ACID; PRAVASTATIN; RAMIPRIL; SIMVASTATIN;

ATHEROGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; CHRONIC DISEASE; CLINICAL OBSERVATION; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE COURSE; DRUG ACTIVITY; DRUG EFFECT; DRUG RESPONSE; DRUG USE; DYSLIPIDEMIA; EXPERIMENTAL MODEL; FIBROGENESIS; HUMAN; HYPOTHESIS; INFLAMMATION; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY STRUCTURE; LIPID OXIDATION; MORBIDITY; MORTALITY; NONHUMAN; OXIDATIVE STRESS; PATIENT; POPULATION RESEARCH; PROTECTION; PROTEIN ANALYSIS; PROTEINURIA; REGULATORY MECHANISM; REMISSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTI-INFLAMMATORY AGENTS; BLOOD GLUCOSE; BLOOD PRESSURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; KIDNEY FAILURE, CHRONIC; LIPID PEROXIDATION; LIPIDS; NITRIC OXIDE; OXIDATIVE STRESS; PROTEINURIA;

ANIMALIA;

EID: 11844258767     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2004.09.029     Document Type: Conference Paper

References (27)

1. P.W. Wilson, R.B. D'Agostino, D. Levy Prediction of coronary heart disease using risk factor categories Circulation 97 1998 1837 1847
2. C. Wanner, T. Quaschning Dyslipidemia and renal disease Pathogenesis and clinical consequences Curr Opin Nephrol Hypertens 10 2001 195 201
3. H.S. Lee, J.S. Lee, H.I. Koh Intraglomerular lipid deposition in routine biopsies Clin Nephrol 36 1991 67 75
4. M. Ravid, D. Brosh, D. Ravid-Safran Main risk factors for nephropathy in type 2 diabetes are cholesterol, blood pressure, and hyperglycemia Arch Intern Med 158 1998 998 1004
5. N.D. Vaziri Molecular mechanisms of lipid disorders in NS Kidney Int 63 2003 1964 1976
6. B. Lamarche, I. Lemieux, J.P. Despres The small, dense LDL phenotype and the risk of CHD Epidemiology, patho-physiology and therapeutic aspects Diabetes Metab 25 1999 199 211
7. W. Gwinner, H.J. Grone Role of reactive oxygen species in glomerulonephritis Nephrol Dial Transplant 15 2000 1127 1132
8. H. Scheuer, W. Gwinner, J. Hohbach Oxidant stress in hyperlipidemia- induced renal damage Am J Physiol Renal Physiol 278 2000 F63 F74
9. D.J. Maron, S. Fazio, M.F. Linton Current perspectives on statins Circulation 101 2000 207 213
10. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals. A randomised placebo-controlled trial Lancet 360 2002 7 22
11. S. Bellosta, N. Ferri, F. Bernini Non-lipid-related effects of statins Ann Med 32 2000 164 176
12. S. Wassmann, U. Laufs, A.T. Baumer HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of ROS Hypertension 37 2001 1450 1457
13. W. Ni, K. Egashira, C. Kataoka Antiinflammatory and antiarteriosclerotic actions of HMG-CoA reductase inhibitors in a rat model of chronic inhibition of nitric oxide synthesis Circ Res 89 2001 415 421
14. J.C. Mason, Z. Ahmed, R. Mankoff Statin-induced expression of decay-accelerating factor protects vascular endothelium against complement-mediated injury Circ Res 91 2001 696 703
15. S. Kinlay, A.P. Selwyn Effects of statins on inflammation in patients with acute and chronic coronary syndromes Am J Cardiol 91 2003 9B 13B
16. L.F. Fried, T.J. Orchard, B.L. Kasiske Effect of lipid reduction on the progression of renal disease A meta-analysis Kidney Int 59 2001 260 269
17. T.M. Lee, S.F. Su, C.H. Tsai Effect of pravastatin on proteinuria in patients with well-controlled hypertension Hypertension 40 2002 67 73
18. S. Bianchi, R. Bigazzi, A. Caiazza A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease Am J Kidney Dis 41 2003 565 570
19. R. Agarwal, R.C. Campbell, D.G. Warnock Oxidative stress in hypertension and chronic kidney disease Role of angiotensin II Semin Nephrol 24 2004 101 114
20. P. Ruggenenti, A. Schieppati, G. Remuzzi Progression, remission, regression of chronic renal diseases Lancet 357 2001 1601 1608
21. R.T. Gansevoort, W.J. Sluiter, M.H. Hemmelder Antiproteinuric effect of blood-pressure-lowering agents A meta-analysis of comparative trials Nephrol Dial Transplant 10 1995 1963 1974
22. P. Ruggenenti, N. Mise, R. Pisoni Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies Circulation 107 2003 586 592
23. M. Di Napoli, F. Papa ACE inhibitor use is associated with reduced plasma concentration of C-reactive protein in patients with first-ever ischemic stroke Stroke 34 2003 2922 2929
24. C. Zoja, D. Corna, D. Rottoli Effect of combining ACE inhibitor and statin in severe experimental nephropathy Kidney Int 61 2002 1635 1645
25. C. Zoja, D. Corna, D. Camozzi How to fully protect the kidney in a severe model of progressive nephropathy A multidrug approach J Am Soc Nephrol 13 2002 2898 2908
26. P. Gaede, P. Vedel, N. Larsen Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes N Engl J Med 348 2003 383 393
27. J.N. Poynter, G. Rennert, J.D. Bonner HMG CoA reductase inhibitors and the risk of colorectal cancer J Clin Oncol 22 suppl 2004 1